Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch
Hemostemix (OTCQB:HMTXF) announced the appointment of Croom Lawrence as Chief Commercialization Officer. The company has partnered with Lawrence to offer MCI Screen, an FDA-approved and insurer-reimbursed advanced cognitive test for Vascular Dementia. The company noted that their ACP-01 treatment has shown clinical success in reversing vascular dementia in one patient for over ten years.
Hemostemix (OTCQB:HMTXF) ha annunciato la nomina di Croom Lawrence come Chief Commercialization Officer. L'azienda ha collaborato con Lawrence per offrire MCI Screen, un test cognitivo avanzato approvato dalla FDA e rimborsato dagli assicuratori per la Demenza Vascolare. La società ha evidenziato che il loro trattamento ACP-01 ha mostrato successo clinico nel invertire la demenza vascolare in un paziente per oltre dieci anni.
Hemostemix (OTCQB:HMTXF) anunció el nombramiento de Croom Lawrence como Chief Commercialization Officer. La empresa se ha asociado con Lawrence para ofrecer MCI Screen, una prueba cognitiva avanzada aprobada por la FDA y reembolsada por aseguradoras para la Demencia Vascular. La compañía señaló que su tratamiento ACP-01 ha demostrado éxito clínico al revertir la demencia vascular en un paciente durante más de diez años.
Hemostemix (OTCQB:HMTXF)는 Croom Lawrence를 최고 상업화 책임자(Chief Commercialization Officer)로 임명했다고 발표했습니다. 회사는 Lawrence와 협력하여 FDA 승인 및 보험사 보상을 받는 혈관성 치매용 고급 인지 검사인 MCI Screen을 제공하고 있습니다. 회사는 ACP-01 치료가 한 환자에서 10년 넘게 혈관성 치매를 역전시키는 임상적 성공을 보였다고 밝혔습니다.
Hemostemix (OTCQB:HMTXF) a annoncé la nomination de Croom Lawrence en tant que Chief Commercialization Officer. La société s'est associée à Lawrence pour proposer MCI Screen, un test cognitif avancé approuvé par la FDA et remboursé par les assureurs pour la démence vasculaire. La société a souligné que leur traitement ACP-01 a démontré un succès clinique en inversant la démence vasculaire chez un patient depuis plus de dix ans.
Hemostemix (OTCQB:HMTXF) gab die Ernennung von Croom Lawrence zum Chief Commercialization Officer bekannt. Das Unternehmen arbeitet mit Lawrence zusammen, um MCI Screen anzubieten, einen von der FDA zugelassenen und von Versicherern erstatteten fortschrittlichen kognitiven Test für vaskuläre Demenz. Das Unternehmen stellte fest, dass ihre Behandlung ACP-01 klinische Erfolge bei der Umkehrung vaskulärer Demenz bei einem Patienten über mehr als zehn Jahre gezeigt hat.
- Appointment of Chief Commercialization Officer strengthens leadership team
- Partnership to offer FDA-approved and reimbursable MCI Screen test
- Clinical evidence of ACP-01 effectiveness in vascular dementia treatment
- Limited clinical evidence with only one patient case study reported
Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III autologous stem cell therapy company and Mr. Croom Lawrence are pleased to announce Croom has joined Hemostemix as its Chief Commercialization Officer, and partnered to offer MCI Screen through Hemostemix.
MCI Screen is an FDA-approved and insurer-reimbursed advanced cognitive test for Vascular Dementia. Clinically, ACP-01 has been observed to reverse vascular dementia for more than ten years in one patient (Mrs L.).
About Croom Lawrence
Croom Lawrence is a seasoned biopharmaceutical executive with over 25 years of experience driving commercialization strategies across regenerative medicine, cell therapy, advanced biologics and diagnostics. He has successfully launched multiple breakthrough therapies, built and led high-performing global marketing and sales teams, and secured strategic partnerships with top-tier pharma and healthcare providers. His deep understanding of market access, reimbursement, and regulatory navigation positions him as a key asset to Hemostemix. By leveraging Croom's expertise, Hemostemix can accelerate the global adoption of ACP-01, expand its clinical and commercial footprint, and build sustainable revenue channels that align with our mission to restore health and save lives.
"I am very pleased to welcome Croom Lawrence as our Chief Commercialization Officer. Croom brings a rare blend of strategic insight and executional excellence, honed through decades of leadership in biotech commercialization. His track record in building global markets, negotiating complex partnerships, and accelerating the path from bench to bedside is unmatched. With Croom leading our commercialization efforts, Hemostemix is poised to unlock the full value of ACP-01 and transform patient care worldwide. The revenue share agreement with MCI Screen generates immediate significant revenue synergies," Smeenk said.
Revenue Sharing
Hemostemix and Acurist.AI (Croom Lawrence) have agreed to share revenue from each cognitive assessment such that
Acurist.AI adds to Hemostemix's Ability to Screen for Vascular Dementia
Powered by a normative database of 2 million data points, Acurist.AI's advanced cognitive test is
A New Path Forward for Patients and Families
"This is a highly accurate assessment that is completed in a 10-12 minutes video call," stated Thomas Smeenk, CEO. "This partnership brings together Hemostemix's regenerative medicine with Acurist.AI's insurer-reimbursed, cutting-edge diagnostics. It provides the physicians assessing patients for vascular dementia, including assessments for the Phase I trial, with a highly accurate early detection of cognitive impairment. With additional assessment, physicians will understand if the impairment is Vascular Dementia and treatable with ACP-01."
Croom Lawrence, Co-Founder of Acurist.AI, added, "Our goal is to change lives through upfront precision cognitive testing, followed by targeted treatment. This combination holds the promise to significantly reduce the massive cost of long-term memory care, as we scale."
Learn More or Enroll Today at www.VesCell.Health
Hemostemix's original trademark for ACP-01 was VesCell(TM). In a word, VesCell(TM) describes angiogensis as the formation of new neo-circulation. Families seeking answers to various forms of cardiovascular disease including vascular dementia can visit www.hemostemix.com to learn more. Families seeking the MCI Screen test may book a consultation with Croom Lawrence at www.Vescell.Health
For more information:
Thomas Smeenk - tsmeenk@hemostemix.com | 905-580-4170
Croom Lawrence - clawrence@hemostemix.com | 540-878-6754
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, ACP-01. Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder
EM: tsmeenk@hemostemix.com PH: 905-580-4170
Croom Lawrence - croom@acurist.ai | 540-878-6754
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of MCI Screen, and its lead product ACP-01, and the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Programs. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257088
FAQ
Who is the new Chief Commercialization Officer of Hemostemix (HMTXF)?
What is MCI Screen and how is it related to Hemostemix (HMTXF)?
What clinical results has Hemostemix (HMTXF) shown for vascular dementia treatment?
Is MCI Screen FDA approved for vascular dementia testing?
